Last checked at 
19 Apr 2021 07:00
LEI: 549300Q7EXQQH6KF7Z84
19 April 2021
RTW Venture Fund Limited
Portfolio Company Update: Biomea IPO
Biomea Prices $153 Million IPO
RTW Venture Fund Limited (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors, is pleased to note the 15 April 2021 announcement by one of its portfolio companies, Biomea Fusion, Inc. ("Biomea") regarding its pricing of a $153 million initial public offering ("IPO") and admission to trade on Nasdaq Global Market under ticker "BMEA".
Biomea is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea is advancing its lead preclinical program BF-219, an irreversible menin inhibitor, for the treatment of menin-dependent cancers.
Prior to IPO, the Company together with other funds managed by RTW Investments, LP (the "Investment Manager") participated in a $56 million Series A financing round in Biomea in December 2020.
Biomea's IPO raised $153 million by offering 9 million shares at $17.00 per share. On the first day of trading, Biomea's share price increased by 9.41% to close at $18.11 per share.
Biomea's IPO pricing announcement can be accessed on its website at: www.biomeafusion.com, the full text of which is contained below.
For Further Information
RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business OfficerAlexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Senior Business Development Associate
Buchanan +44 (0)20 7466 5107Charles Ryland
Henry Wilson
George Beale
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
Biomea Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Biomea. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biomea, are expected to be $153.0 million. Biomea's common stock is expected to begin trading on The Nasdaq Global Select Market on April 16, 2021, under the ticker symbol "BMEA." The offering is expected to close on April 20, 2021, subject to satisfaction of customary closing conditions. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.
Registration statements relating to the securities has been filed with the Securities and Exchange Commission and was declared effective on April 15, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained from, when available from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Contact:Liz Melonelm@biomeafusion.com